콘텐츠로 건너뛰기
Merck
모든 사진(1)

Key Documents

71400-M

Sigma-Aldrich

Rosetta 2(DE3) Singles Competent Cells - Novagen

Escherichia coli, rod shaped

동의어(들):

BL21 derivatives

로그인조직 및 계약 가격 보기


About This Item

UNSPSC 코드:
41106202
NACRES:
NA.81

product name

Rosetta 2(DE3) Singles Competent Cells - Novagen, Novagen′s Rosetta 2 host strains are BL21 derivatives designed to enhance the expression of eukaryotic proteins that contain codons rarely used in E. coli.

생물학적 소스

Escherichia coli

Quality Level

제조업체/상표

Novagen®

저장 조건

OK to freeze

성장 모드

adherent or suspension

형태학

rod shaped

기술

microbiological culture: suitable

세포 형질전환

transformation efficiency: >2×106 cfu/μg

배송 상태

dry ice

저장 온도

−70°C

일반 설명

Genotype: F-ompT hsdSB(rB- mB-) gal dcm (DE3) pRARE2 (CamR)





This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges us to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.
A common method for transformation of DNA plasmids into E. coli is the use of chemically competent cells. Although competent cells can be prepared in the laboratory, greater efficiency, reproducibility, and convenience are achieved using Novagen prepared competent cells. Novagen® Singles Competent Cells are designed for ultimate convenience and reliability in plasmid transformation. Chemically competent cells are prepared using an optimized method. Cells are provided in 50µl volumes, eliminating the need to aliquot, freeze/thaw, or waste partially used vials, saving time and money and ensuring reliable cell performance. To use, simply thaw, add DNA, incubate 5 minutes on ice, heat shock for 30 seconds, place on ice for 2 minutes, and add SOC medium.T7 expression strains are lysogens of bacteriophageDE3, as indicated by the (DE3). These hosts carry achromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in appropriate T7 expression vectors, using IPTG as an inducer.
Rosetta 2 host strains are BL21 derivatives designed to enhance the expression of eukaryotic proteins that contain codons rarely used in E. coli. These strains supply tRNAs for 7 rare codones (AGA, AGG, AUA, CUA, GGA, CCC, and CGG) on a compatible chloramphenicol-resistant plasmid. The tRNA genes are driven by their native promoters.

DE3 indicates that the host is a lysogen of λDE3, and therefore carries a chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in pET vectors by induction with IPTG.
Novagen′s Rosetta 2 host strains are BL21 derivatives designed to enhance the expression of eukaryotic proteins that contain codons rarely used in E. coli.

성분

•11 rxn or 22 rxnRosetta 2(DE3) Competent Cells

•2 × 2 ml or 4 × 2 mlSOC Medium

•10 µlTest Plasmid

경고

Toxicity: Multiple Toxicity Values, refer to MSDS (O)

법적 정보

NOVAGEN is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

10 - Combustible liquids

WGK

WGK 2


시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Fatma Betul Ertem et al.
STAR protocols, 3(1), 101158-101158 (2022-02-24)
The SARS-CoV-2 main protease of (Mpro) is an important target for SARS-CoV-2 related drug repurposing and development studies. Here, we describe the steps for structural characterization of SARS-CoV-2 Mpro, starting from plasmid preparation and protein purification. We detail the steps
Serdar Durdagi et al.
Structure (London, England : 1993), 29(12), 1382-1396 (2021-08-18)
The COVID-19 pandemic has resulted in 198 million reported infections and more than 4 million deaths as of July 2021 (covid19.who.int). Research to identify effective therapies for COVID-19 includes: (1) designing a vaccine as future protection; (2) de novo drug

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.